Latest Conference Articles

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Adding Zynyz to carboplatin and paclitaxel prolonged survival without progression in chemotherapy-naive recurrent or metastatic squamous cell carcinoma of the anal canal.

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial chemoembolization.

Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy.

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression.

Patients with HER2-positive breast cancer benefitted from treatment with Enhertu regardless of brain metastasis.

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.

As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.

Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.

Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.

After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.

Patients with multiple myeloma now have several available treatment options, so it’s important to have answers to some of the frequently asked questions.

Two breast oncologists responded to frequently asked questions about metastatic breast cancer.

An expert explained the importance of understanding different subtypes of metastatic breast cancer and available treatment options based on biomarker testing.

Here are answers to 10 questions patients asked at the CURE® Educated Patient® Metastatic Breast Cancer Summit about scans, treatment and clinical trials.

Before enrolling in a clinical trial for metastatic breast cancer, it’s important to know which are best suited for each individual, an expert said.

One specialist explained the ways palliative care, also known as supportive care, can assist patients during a breast cancer journey.

At the CURE® Educated Patient® Breast Cancer Summit, an expert discussed integrative methods that can improve quality of life.

Patients with HR-positive metastatic breast cancer can expect to undergo biomarker testing both at diagnosis and again if the disease progresses.

One expert explained the common side effects at every line of treatment for metastatic HER2-positive breast cancer during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

One expert explains why “the future of precision medicine” has arrived in lung cancer at the CURE® Educated Patient® Lung Cancer Summit.

Tumor characteristics are used to determine the best method of combining therapies with surgery for non-small cell lung cancer, according to a presentation at the CURE® Educated Patient® Lung Cancer Summit.

During the CURE® Educated Patient® Multiple Myeloma Summit, one expert explained the push to make CAR-T cell therapy available for patients sooner.